EP1597267A2 - Pharmacodynamic assay for inhibitors of 11-beta-hydroxysteroid dehydrogenase activity in animal tissues - Google Patents

Pharmacodynamic assay for inhibitors of 11-beta-hydroxysteroid dehydrogenase activity in animal tissues

Info

Publication number
EP1597267A2
EP1597267A2 EP04711932A EP04711932A EP1597267A2 EP 1597267 A2 EP1597267 A2 EP 1597267A2 EP 04711932 A EP04711932 A EP 04711932A EP 04711932 A EP04711932 A EP 04711932A EP 1597267 A2 EP1597267 A2 EP 1597267A2
Authority
EP
European Patent Office
Prior art keywords
llβ
hydroxysteroid dehydrogenase
steroid hormone
whole animal
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04711932A
Other languages
German (de)
French (fr)
Other versions
EP1597267A4 (en
Inventor
Gloria Chan Koo
Kashmira Shah
Jianying Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1597267A2 publication Critical patent/EP1597267A2/en
Publication of EP1597267A4 publication Critical patent/EP1597267A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • the present invention is concerned with a novel method to measure ll ⁇ - hydroxy steroi d dehydrogenase activity in intact whole animal tissues in the presence of systemically administered inhibitors of the enzyme.
  • the method also provides a pharmacodynamic assessment of inhibitor exposure in vivo.
  • Metabolic Syndrome obesity is thought to promote insulin resistance, diabetes, dyslipidemia, hypertension, and increased cardiovascular risk.
  • the best predictor of Metabolic Syndrome is not overall fat mass but rather visceral adiposity. Prolonged systemic exposure to glucocorticoids induces fat redistribution toward the viscera and pathological sequelae closely resembling the Metabolic Syndrome.
  • ll ⁇ -HSDl ll ⁇ -hydroxysteroid dehydrogenase type 1
  • ll ⁇ -HSDl -knockout mice develop normally, and are viable, fertile, and normotensive. Moreover, the model demonstrates that ll ⁇ -HSDl is the major ll ⁇ -reductase since adrenalectomized ll ⁇ -HSDl -knockouts cannot convert 11-dehydrocorticosterone to active corticosterone.
  • the knockout mice have impaired induction of key gluconeogenic enzymes, decreased hyperglycemic response to stress or obesity, increased insulin sensitivity and improved glucose tolerance.
  • mice which overexpress rat ll ⁇ -HSDl selectively in adipose tissue show all of the sequelae of Metabolic Syndrome. These mice develop visceral adiposity which is exacerbated by high-fat diet. They have pronounced insulin-resistant diabetes, exhibit hyperlipidemia, and are hypertensive. The animals have increased adiposity, and increased levels of corticosterone in adipose. However, they do not have improved circulating levels of corticosterone. Most importantly, the phenotype is produced by levels of 1 l ⁇ -HSDl overexpression equivalent to, or in fact slightly less than, the increases in ll ⁇ -HSDl activity observed in the adipose from obese humans.
  • the type 1 isoform is also highly expressed in the liver. Gluconeogenesis in the liver is reduced when the ll ⁇ -HSDl gene is knocked-out resulting in lower fasting glucose levels [Y. Kotelevtsev et al., "ll ⁇ -HSD type 1 knockout mice show attenuated glucocorticoid- inducible responses and resist hyperglycemia on obesity or stress," Proc. Natl. Acad. Sci exert 94: 14924-14929 (1997)].
  • the present invention provides a novel method to measure enzyme activity of 1 l ⁇ -hydroxysteroid dehydrogenase in intact primary animal tissues without the need to supplement cofactors for the enzyme.
  • the present assay provides for a pharmacodynamic assessment of inhibitor exposure in vivo with little disturbance of the equilibrium achieved in situ.
  • the present invention is concerned with a novel pharmacodynamic assay useful to measure the ability of a systemically administered compound to modulate the interconversion between 11-keto and ll ⁇ -hydroxy steroid hormones mediated by 1 l ⁇ -hydroxysteroid dehydrogenase in various tissues of a whole animal.
  • Inhibitors of the type 1 isoform (ll ⁇ -HSDl) may be useful to treat type 2 diabetes, Metabolic Syndrome, and other metabolic disorders.
  • FIGURE 1 shows the inhibition by Compound A of the conversion of [3H]- cortisone to [3H]-cortisol in three different mouse tissues, 4 hours after oral dosing of the compound at 1, 3, and 10 milligrams per kilogram (mpk).
  • CPM represents counts-per-minute of [3H]-cortisol obtained in the scintillation proximity assay (SPA).
  • FIGURE 2 shows the inhibition by Compound B of the conversion of [3H]- cortisone to [3H]-cortisol in three different rat tissues, 19 hours after oral dosing of the compound at 60 mpk.
  • CPM represents counts-per-minute of [3H] -cortisol obtained in the scintillation proximity assay (SPA).
  • FIGURE 3 shows the in vitro inhibition by Compound C of the conversion of [3H]-cortisone to [3H]-cortisol in two different rhesus monkey tissues. 1 ⁇ M of Compound C was added to the tissues 15 min prior to the addition of [3H]-cortisone. CPM represents counts- per-minute of [3H]-cortisol obtained in the scintillation proximity assay (SPA).
  • SPA scintillation proximity assay
  • the present invention provides an ex vivo assay to measure a compound's ability to modulate ll ⁇ -hydroxysteroid dehydrogenase enzyme activity as assessed by the conversion of a steroid hormone substrate for the enzyme to its corresponding steroid hormone product.
  • the assay of the present invention comprises the steps of:
  • the ll ⁇ -hydroxysteroid dehydrogenase is ll ⁇ -hydroxysteroid dehydrogenase type 1.
  • the ll ⁇ -hydroxysteroid dehydrogenase is ll ⁇ -hydroxysteroid dehydrogenase type 2.
  • Substrates for the ll ⁇ -HSD type 1 isoform include the 11-keto steroid hormones cortisone, dehydrocorticosterone, and prednisone, which are converted by the enzyme into cortisol, corticosterone, and prednisolone, respectively.
  • Substrates for the 1 l ⁇ -HSD type 2 isoform include the ll ⁇ -hydroxy steroid hormones cortisol, corticosterone, and prednisolone, which are converted by the enzyme into cortisone, dehydrocorticosterone, and prednisone, respectively.
  • the test compound to be evaluated is systemically administered to the whole animal.
  • Systemic administration may be either by the oral or parenteral route.
  • Parenteral administration may be by intravenous (IV), subcutaneous (SC), or intraperitoneal (IP) route.
  • IV intravenous
  • SC subcutaneous
  • IP intraperitoneal
  • the length of exposure of the test compound in the whole animal is from about 10 minutes to about 3 days after dosage.
  • Compounds can also be repeatedly dosed to the animals for weeks to months duration. In one embodiment the length of exposure is from about one hour to about 24 hours.
  • the whole animal is selected from the group consisting of rat, mouse, rabbit, guinea pig, dog, non-human primate, and human.
  • the whole animal is a rat, mouse, or non-human primate.
  • the non-human primate is a rhesus monkey.
  • the tissue to be assayed from the whole animal is selected from the group consisting of liver, brain, muscle, lung, pancreas, kidney, blood, and adipose.
  • the tissue is removed from the whole animal by surgical procedure, dissection, or biopsy.
  • the tissue removed from the whole animal is weighed prior to addition of a certain volume of the culture medium.
  • the ratio of the weight of the tissue (in milligrams) to volume of culture medium added (in milliliters) is from about 1:3 to about 1:10. In a class of this embodiment, the ratio is about 1:5.
  • the tissue may then be minced as with scissors prior to incubation. Incubation is effectively carried out at 37 °C under a carbon dioxide atmosphere for about 10 minutes to about 24 hours depending on the tissue. Cells are not isolated from the tissues, nor is any homogenization carried out.
  • Harvesting comprises decanting off the supernatant followed by optional centrifuging of the supernatant and decanting to remove cellular debris.
  • the extent of conversion of enzyme substrate to enzyme product in the supernatant is then measured either by high-performance liquid chromatography (HPLC) or by using an antibody to enzyme product using a scintillation proximity assay (SPA).
  • HPLC high-performance liquid chromatography
  • SPA scintillation proximity assay
  • the HPLC method to assay ll ⁇ -HSDl activity uses either cold cortisone or [3H] -cortisone.
  • the SPA assay utilizes [3H] -cortisone and is described in the Supporting Information for the J. Med. Chem., 45: 3813-3815 (2002) article available via the Internet at http://pubs.acs.org. The contents of this article are incorporated by reference herein in their entirety.
  • the Example detailed below detects the enzymatic activity of 1 l ⁇ -HSDl, the conversion of cortisone to cortisol, in the absence or presence of inhibitor compounds. If an inhibitor compound for ll ⁇ -HSDl activity is present, conversion will be inhibited, and the degree of inhibition is a measure of the effect of the inhibitor at a respective concentration.
  • Tissues of any type such as for example, adipose, liver, brain, muscle, etc., were removed, and put in 24-well plates. They were kept on ice and weighed (about 200 mg).
  • RPMI fetal calf serum
  • GTBCO penicillin- streptomycin
  • Tissue was then minced into 2-3 mm pieces with scissors, and subsequently incubated at 37 °C in a 5-7% CO2 atmosphere for 10 min to 3 h, depending on the tissue. Cells were not isolated from the tissues, nor was any homogenization performed.
  • mice e.g. mice or rats
  • test inhibitor compound was administered by the oral, IV, SC or IP route. After a period of time, (10 min to 3 days), the animals were euthanized and then exsanguinated by cardiac bleeding. Tissues were removed and placed in 24 well-plates. They were kept on ice, and weighed (about 200 mg).
  • RPMI fetal calf serum
  • penicillin-streptomycin stock solutions from GIBCO
  • RPMI fetal calf serum
  • penicillin-streptomycin stock solutions from GIBCO
  • nM [3H] -cortisone was added to each piece of tissue.
  • the total volume (mL's) added was equivalent to about 5 times the mass of tissue (milligrams).
  • Tissue was then minced into 2-3 mm pieces with scissors, and subsequently incubated at 37 °C in a 5-7% CO 2 atmosphere for 10 min to 3 h, depending on the tissue. Cells were not isolated from the tissues, nor was any homogenization performed. At the end of the incubation period, supernatant was collected.
  • FIGURE 1 shows the amount of counts obtained and the extent of inhibition of the conversion of cortisone to cortisol by three different doses of Compound A.
  • FIGURE 2 shows the activity of Compound B in three different rat tissues when dosed orally by gavage at 60 mpk for 19 hours before euthanasia.
  • CPM represents counts-per- minute of [3H]-cortisol in the scintillation proximity assay (SPA).
  • FIGURE 3 shows the activity of Compound C in two different rhesus monkey tissues when incubated for 15 min at 37 °C before addition of the [3H]-cortisone.
  • CPM represents counts-per-minute of [3H]-cortisol in the scintillation proximity assay (SPA).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A novel method is provided to measure 11β-hydroxysteroid dehydrogenase activity in intact whole animal tissues in the presence of systemically or ex vivo administered inhibitors of the enzyme. Inhibitors of the type 1 isoform (11β -HSD1) may be useful to treat type 2 diabetes, Metabolic Syndrome, and other metabolic disorders.

Description

TITLE OF THE INVENTION
PHARMACODYNAMIC ASSAY FOR INHTOITORS OF 11-BETA-HYDROXYSTEROID
DEHYDROGENASE ACTIVITY EN ANTMAL TISSUES
FIELD OF THE INVENTION
The present invention is concerned with a novel method to measure llβ- hydroxy steroi d dehydrogenase activity in intact whole animal tissues in the presence of systemically administered inhibitors of the enzyme. The method also provides a pharmacodynamic assessment of inhibitor exposure in vivo.
BACKGROUND OF THE INVENTION
Excessive levels of glucocorticoids can cause metabolic complications. In the Metabolic Syndrome, obesity is thought to promote insulin resistance, diabetes, dyslipidemia, hypertension, and increased cardiovascular risk. The best predictor of Metabolic Syndrome is not overall fat mass but rather visceral adiposity. Prolonged systemic exposure to glucocorticoids induces fat redistribution toward the viscera and pathological sequelae closely resembling the Metabolic Syndrome.
Though the Metabolic Syndrome is not generally associated with increased systemic concentrations of glucocorticoids, hormone actions on target tissues depend on intracellular metabolism as well as on circulating glucocorticoid levels. In particular, the enzyme llβ-hydroxysteroid dehydrogenase type 1 (llβ-HSDl) plays a central role in regulating intracellular concentrations of glucocorticoids by regenerating the active molecules (cortisol and corticosterone in humans and rodents, respectively) from the inactive 11-keto precursors (cortisone and 11-dehydrocorticosterone) [see J. R. Seckl, et al., "llβ-HSD type 1 - a tissue- specific amplifier of glucocorticoid action, Endocrinology, 142: 1371-1376 (2001) and Y. Kotelevtsev, et al., "llβ-Hydroxysteroid dehydrogenases: key modulators of glucocorticoid action in vivo," Curr. Opin. Endocrinol. Diabetes, 6: 191-198 (1999)] A second isoform of the enzyme llβ-hydroxysteroid dehydrogenase type 2 (llβ-HSD2), which has 20% homology to llβ-HSDl, inactivates cortisol by converting it into cortisone. Over the past several years a substantial body of data has been accumulated from both murine genetic models and human studies implicating llβ-HSDl as a driver of Metabolic Syndrome.
Cortisone
llβ-HSDl -knockout mice develop normally, and are viable, fertile, and normotensive. Moreover, the model demonstrates that llβ-HSDl is the major llβ-reductase since adrenalectomized llβ-HSDl -knockouts cannot convert 11-dehydrocorticosterone to active corticosterone. The knockout mice have impaired induction of key gluconeogenic enzymes, decreased hyperglycemic response to stress or obesity, increased insulin sensitivity and improved glucose tolerance. These findings are consistent with the increased insulin sensitivity observed in normal human volunteers treated with the HSD inhibitor carbenoxolone. The null mice also show a higher increase in diet-dependent in HDL levels, compared to wild type controls. When backcrossed to the obesity sensitive C57BL6 background, deletion of llβ-HSDl also inhibits diet-induced weight gain. It is important to note that the knockout perturbs the HPA axis, increasing plasma levels of corticosterone and ACTH by two- to three-fold, respectively, during nadir in the diurnal cycle while still having favorable effects on Metabolic Syndrome. These results demonstrate that it is the intracellular, not the systemic, levels of glucocorticoids which regulate the metabolic parameters.
Transgenic mice which overexpress rat llβ-HSDl selectively in adipose tissue show all of the sequelae of Metabolic Syndrome. These mice develop visceral adiposity which is exacerbated by high-fat diet. They have pronounced insulin-resistant diabetes, exhibit hyperlipidemia, and are hypertensive. The animals have increased adiposity, and increased levels of corticosterone in adipose. However, they do not have improved circulating levels of corticosterone. Most importantly, the phenotype is produced by levels of 1 lβ-HSDl overexpression equivalent to, or in fact slightly less than, the increases in llβ-HSDl activity observed in the adipose from obese humans. There is a 2.7-fold increase in llβ-HSDl activity in the adipose of these mice, and 3-fold and 3.5-fold increases in 1 lβ-HSDl mRNA and activity in adipose of obese versus lean humans. Transgenic overexpression of llβ-HSDl in the liver also induces symptoms of Metabolic Syndrome, although the extent of the phenotype appears to be somewhat milder than that produced by overexpression in adipose. Taken together, the human and murine data suggest that inhibition of 1 lβ-HSDl may be a useful therapeutic target for Metabolic Syndrome.
The type 1 isoform is also highly expressed in the liver. Gluconeogenesis in the liver is reduced when the llβ-HSDl gene is knocked-out resulting in lower fasting glucose levels [Y. Kotelevtsev et al., "llβ-HSD type 1 knockout mice show attenuated glucocorticoid- inducible responses and resist hyperglycemia on obesity or stress," Proc. Natl. Acad. Sci„ 94: 14924-14929 (1997)].
Additional evidence also supports the hypothesis that inhibition of llβ-HSDl may constitute a useful approach to the treatment of type 2 diabetes without the risk of hypertension [for example, see T. Barf, et al., "Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11 β-Hydroxysteroid Dehydrogenase Type 1 ," J. Med. Chem.. 45: 3813-3815 (2002)].
Only a limited number of potentially therapeutically useful inhibitors of llβ- HSDl has been reported. For example, a class of arylsulfonamidothiazoles has been disclosed in International Patent Publications WO 01/90092 (29 November 2001) and WO 01/90094 (29 November 2001), assigned to Biovitrum AB, and published in J. Med. Chem., 45: 3813-3815 (2002). In these publications, the ability of the disclosed compounds to inhibit human or mouse llβ-HSDl activity was assessed using an in vitro scintillation proximity assay (SPA) with recombinant human or murine enzyme with a substrate/cofactor mixture of tritiated cortisone/NADPH and different concentrations of inhibitor.
Cells isolated from adipose tissue or tissue homogenates have also been employed to quantify llβ-HSDl activity when exposed in vitro to inhibitors [see U.S. Patent No. 6,368,816 (Apr. 9, 2002) assigned to The University of Edinburgh]. However, this in vitro method suffers from the disadvantage that cells have to be isolated in order to measure enzyme activity and therefore does not accurately assess inhibitor exposure in vivo.
The present invention provides a novel method to measure enzyme activity of 1 lβ-hydroxysteroid dehydrogenase in intact primary animal tissues without the need to supplement cofactors for the enzyme. The present assay provides for a pharmacodynamic assessment of inhibitor exposure in vivo with little disturbance of the equilibrium achieved in situ.
SUMMARY OF THE INVENTION
The present invention is concerned with a novel pharmacodynamic assay useful to measure the ability of a systemically administered compound to modulate the interconversion between 11-keto and llβ-hydroxy steroid hormones mediated by 1 lβ-hydroxysteroid dehydrogenase in various tissues of a whole animal. Inhibitors of the type 1 isoform (llβ-HSDl) may be useful to treat type 2 diabetes, Metabolic Syndrome, and other metabolic disorders.
BRIEF DESCRIPTION OF THE FIGURES
FIGURE 1 shows the inhibition by Compound A of the conversion of [3H]- cortisone to [3H]-cortisol in three different mouse tissues, 4 hours after oral dosing of the compound at 1, 3, and 10 milligrams per kilogram (mpk). CPM represents counts-per-minute of [3H]-cortisol obtained in the scintillation proximity assay (SPA).
FIGURE 2 shows the inhibition by Compound B of the conversion of [3H]- cortisone to [3H]-cortisol in three different rat tissues, 19 hours after oral dosing of the compound at 60 mpk. CPM represents counts-per-minute of [3H] -cortisol obtained in the scintillation proximity assay (SPA).
FIGURE 3 shows the in vitro inhibition by Compound C of the conversion of [3H]-cortisone to [3H]-cortisol in two different rhesus monkey tissues. 1 μM of Compound C was added to the tissues 15 min prior to the addition of [3H]-cortisone. CPM represents counts- per-minute of [3H]-cortisol obtained in the scintillation proximity assay (SPA).
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides an ex vivo assay to measure a compound's ability to modulate llβ-hydroxysteroid dehydrogenase enzyme activity as assessed by the conversion of a steroid hormone substrate for the enzyme to its corresponding steroid hormone product. The assay of the present invention comprises the steps of:
(a) dosing said compound in a whole animal;
(b) removing tissue to be assayed from said whole animal;
(c) adding culture medium containing a steroid hormone substrate for said hydroxysteroid dehydrogenase to said tissue;
(d) incubating said culture medium containing said steroid hormone substrate;
(e) harvesting said culture medium; and
(f) assessing the extent of conversion of said added steroid hormone substrate to steroid hormone product.
In one embodiment of the assay of the present invention, the llβ-hydroxysteroid dehydrogenase is llβ-hydroxysteroid dehydrogenase type 1. In a second embodiment of the assay of the present invention, the llβ-hydroxysteroid dehydrogenase is llβ-hydroxysteroid dehydrogenase type 2. Substrates for the llβ-HSD type 1 isoform include the 11-keto steroid hormones cortisone, dehydrocorticosterone, and prednisone, which are converted by the enzyme into cortisol, corticosterone, and prednisolone, respectively.
Substrates for the 1 lβ-HSD type 2 isoform include the llβ-hydroxy steroid hormones cortisol, corticosterone, and prednisolone, which are converted by the enzyme into cortisone, dehydrocorticosterone, and prednisone, respectively.
The test compound to be evaluated is systemically administered to the whole animal. Systemic administration may be either by the oral or parenteral route. Parenteral administration may be by intravenous (IV), subcutaneous (SC), or intraperitoneal (IP) route. The length of exposure of the test compound in the whole animal is from about 10 minutes to about 3 days after dosage. Compounds can also be repeatedly dosed to the animals for weeks to months duration. In one embodiment the length of exposure is from about one hour to about 24 hours.
In a third embodiment of the present invention the whole animal is selected from the group consisting of rat, mouse, rabbit, guinea pig, dog, non-human primate, and human. In a class of this embodiment, the whole animal is a rat, mouse, or non-human primate. In another class of this embodiment, the non-human primate is a rhesus monkey.
In a fourth embodiment, the tissue to be assayed from the whole animal is selected from the group consisting of liver, brain, muscle, lung, pancreas, kidney, blood, and adipose. The tissue is removed from the whole animal by surgical procedure, dissection, or biopsy.
In a fifth embodiment of the present invention, the tissue removed from the whole animal is weighed prior to addition of a certain volume of the culture medium. In a class of this embodiment the ratio of the weight of the tissue (in milligrams) to volume of culture medium added (in milliliters) is from about 1:3 to about 1:10. In a class of this embodiment, the ratio is about 1:5. The tissue may then be minced as with scissors prior to incubation. Incubation is effectively carried out at 37 °C under a carbon dioxide atmosphere for about 10 minutes to about 24 hours depending on the tissue. Cells are not isolated from the tissues, nor is any homogenization carried out.
Harvesting comprises decanting off the supernatant followed by optional centrifuging of the supernatant and decanting to remove cellular debris.
The extent of conversion of enzyme substrate to enzyme product in the supernatant is then measured either by high-performance liquid chromatography (HPLC) or by using an antibody to enzyme product using a scintillation proximity assay (SPA). For example, the HPLC method to assay llβ-HSDl activity uses either cold cortisone or [3H] -cortisone. The SPA assay utilizes [3H] -cortisone and is described in the Supporting Information for the J. Med. Chem., 45: 3813-3815 (2002) article available via the Internet at http://pubs.acs.org. The contents of this article are incorporated by reference herein in their entirety.
The following Examples are provided for purposes of illustration only and are not intended to limit the method of the present invention to the specific conditions for conducting the assay.
EXAMPLE 1
The Example detailed below detects the enzymatic activity of 1 lβ-HSDl, the conversion of cortisone to cortisol, in the absence or presence of inhibitor compounds. If an inhibitor compound for llβ-HSDl activity is present, conversion will be inhibited, and the degree of inhibition is a measure of the effect of the inhibitor at a respective concentration.
General Protocol:
1. Animals were dosed once or multiple times with vehicle or test compounds administered by the oral (PO), IV, SC or IP route.
2. After a period of time, (10 min to 60 days), the animals were euthanized and then exsanguinated by cardiac bleeding. Tissues of any type, such as for example, adipose, liver, brain, muscle, etc., were removed, and put in 24-well plates. They were kept on ice and weighed (about 200 mg).
3. RPMI, supplemented with 5% fetal calf serum (Sigma) and 1% penicillin- streptomycin (GTBCO), and containing 15-20 nM [3H]-cortisone was added to each piece of tissue. The total volume (in mL's) added was equivalent to about 5 times the mass of tissue (in milligrams).
4. Tissue was then minced into 2-3 mm pieces with scissors, and subsequently incubated at 37 °C in a 5-7% CO2 atmosphere for 10 min to 3 h, depending on the tissue. Cells were not isolated from the tissues, nor was any homogenization performed.
5. At the end of the incubation period, supernatant was collected. In some cases the supernatant was spun at 10,000 rpm (Eppendorf centrifuge) for about 2 min to remove cellular debris.
6. The amount of conversion of [3H]-cortisone to [3H]-cortisol in the supernatant was then measured either by HPLC methods or by scintillation proximity assay (SPA) using a commercially available antibody to cortisol. Materials and Methods:
Animals:
Various strains of rat, mouse, rabbit, guinea pig, dog, and non-human primates were used. Human tissues can also be used to test for compound inhibition which can be obtained, for example, by punch biopsy. Animals (e.g. mice or rats) were dosed with vehicle or 0.1 to 1000 mg kg of test inhibitor compound. A more preferred dosing range is 1 to 100 mg/kg of test inhibitor compound. The test inhibitor compound was administered by the oral, IV, SC or IP route. After a period of time, (10 min to 3 days), the animals were euthanized and then exsanguinated by cardiac bleeding. Tissues were removed and placed in 24 well-plates. They were kept on ice, and weighed (about 200 mg). RPMI (GTBCO), supplemented with 5% fetal calf serum (Sigma) and 1% penicillin-streptomycin (stock solutions from GIBCO), and containing 15-20 nM [3H] -cortisone was added to each piece of tissue. The total volume (mL's) added was equivalent to about 5 times the mass of tissue (milligrams). Tissue was then minced into 2-3 mm pieces with scissors, and subsequently incubated at 37 °C in a 5-7% CO2 atmosphere for 10 min to 3 h, depending on the tissue. Cells were not isolated from the tissues, nor was any homogenization performed. At the end of the incubation period, supernatant was collected. In some cases, supernatant was spun at 10,000 rpm (Eppendorf centrifuge) for about 2 min to remove cellular debris. The amount of conversion of [3H]-cortisone to [3H]-cortisol in the supernatant was then measured either by HPLC methods or by using an antibody which specifically binds to [3H]-cortisol. In the latter assay, the [3H]-cortisol was captured by monoclonal antibody to cortisol (Biostride, Inc.) and protein A-coated scintillation impregnated proximity beads [Amersham /Pharmacia, RPN-143]. The amount of radioactive product, [3H]- cortisol, captured on the beads was determined in a microplate liquid scintillation beta counter.
The following conditions were used for the HPLC assay of the conversion of cortisone to cortisol:
200 μL media supernatants were extracted with 1 mL of ethyl acetate. Samples were air dried and resuspended in DMSO containing 16 μg/mL (1:1) of unlabeled cortisone to cortisol (Sigma, St. Louis, MO). Samples were injected into a Shimadzu SCL-10A VP HPLC system using an Inertsil 5-beta M ODS2 column. 100 μL of sample was injected onto the Inertsil column and eluted using 70% Buffer A/30% Buffer B to 40%) buffer A 60% buffer B (Buffer A: 10% Methanol + 90% Water + 0.05% trifluoroacetic acid; Buffer B: 90% Methanol + 10% Water + 0.05% trifluoroacetic acid). [3H]-steroids were detected by a beta-RAM radiochromatography detector (L /US Systems, Tampa, FL). Data was analyzed using WINFLOW (IN/US Systems) and subsequently exported to Microsoft Excel. Relative levels of conversion of [3H]-cortisone to [3HJ-cortisol were used to determine activity and accompanying inhibition by compounds.
Results:
Compound A was given by oral gavage, and 4 h later, mice (n = 4) were euthanized and tissues were removed. Liver, brain, and epididymal white adipose tissue (eWAT) were processed as described above. Liver tissues were incubated for 10 min at 37 °C, and brain and adipose tissues were incubated for 2 h, and supernatants were collected and assayed for cortisol conversion. FIGURE 1 shows the amount of counts obtained and the extent of inhibition of the conversion of cortisone to cortisol by three different doses of Compound A.
EXAMPLE 2 FIGURE 2 shows the activity of Compound B in three different rat tissues when dosed orally by gavage at 60 mpk for 19 hours before euthanasia. CPM represents counts-per- minute of [3H]-cortisol in the scintillation proximity assay (SPA).
EXAMPLE 3 FIGURE 3 shows the activity of Compound C in two different rhesus monkey tissues when incubated for 15 min at 37 °C before addition of the [3H]-cortisone. CPM represents counts-per-minute of [3H]-cortisol in the scintillation proximity assay (SPA).
It will be apparent to those skilled in the art that various modifications and variations can be made to the protocol without departing from the scope of the invention. Thus, the present invention includes modifications and variations that are within the scope of the claims and their equivalents.

Claims

WHAT IS CLAIMED IS:
1. A process for assaying the ability of a compound to inhibit the activity of llβ-hydroxysteroid dehydrogenase in whole animal tissue comprising the steps of:
(a) dosing said compound in a whole animal;
(b) removing tissue to be assayed from said whole animal;
(c) adding culture medium containing a steroid hormone substrate for said hydroxysteroid dehydrogenase to said tissue;
(d) incubating said culture medium containing said steroid hormone substrate;
(e) harvesting said culture medium; and
(f) assessing the extent of conversion of said added steroid hormone substrate to steroid hormone product.
2. The process of Claim 1 wherein said 1 lβ-hydroxysteroid dehydrogenase is llβ-hydroxysteroid dehydrogenase type 1.
3. The process of Claim 1 wherein said llβ-hydroxysteroid dehydrogenase is llβ-hydroxysteroid dehydrogenase type 2.
4. The process of Claim 2 wherein said steroid hormone substrate is cortisone, dehydrocorticosterone, or prednisone.
5. The process of Claim 3 wherein said steroid hormone substrate is cortisol, corticosterone, or prednisolone.
6. The process of Claim 1 wherein said compound is systemically administered to said whole animal.
7. The process of Claim 6 wherein said systemic administration is by the oral or parenteral route.
8. The process of Claim 1 wherein said whole animal is selected from the group consisting of rat, mouse, rabbit, guinea pig, dog, non-human primate, and human.
9. The process of Claim 8 wherein said whole animal is a rat, mouse, or non- human primate.
10. The process of Claim 1 wherein said whole animal tissue is selected from the group liver, brain, muscle, lung, pancreas, kidney, blood, and adipose.
11. The process of Claim 1 wherein said conversion of steroid hormone substrate to steroid hormone product is assessed by a high-performance liquid chromatography method or by a scintillation proximity assay method.
EP04711932A 2003-02-21 2004-02-17 PHARMACODYNAMIC DETERMINATION OF INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE ACTIVITY IN ANIMAL TISSUES Withdrawn EP1597267A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44938103P 2003-02-21 2003-02-21
US449381P 2003-02-21
PCT/US2004/004734 WO2004075831A2 (en) 2003-02-21 2004-02-17 Pharmacodynamic assay for inhibitors of 11-beta-hydroxysteroid dehydrogenase activity in animal tissues

Publications (2)

Publication Number Publication Date
EP1597267A2 true EP1597267A2 (en) 2005-11-23
EP1597267A4 EP1597267A4 (en) 2007-04-18

Family

ID=32927513

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04711932A Withdrawn EP1597267A4 (en) 2003-02-21 2004-02-17 PHARMACODYNAMIC DETERMINATION OF INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE ACTIVITY IN ANIMAL TISSUES

Country Status (4)

Country Link
US (1) US20060159622A1 (en)
EP (1) EP1597267A4 (en)
CA (1) CA2515129A1 (en)
WO (1) WO2004075831A2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883240A (en) * 1995-08-24 1999-03-16 Baker Medical Research Institute Genetic sequences encoding glucocorticoid dehydrogenases and uses therefor
GB9517622D0 (en) * 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
EP1309697A2 (en) * 2000-07-05 2003-05-14 Bayer Aktiengesellschaft Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
GB0105772D0 (en) * 2001-03-08 2001-04-25 Sterix Ltd Use
EA200400707A1 (en) * 2001-11-22 2004-10-28 Биовитрум Аб INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
WO2004027047A2 (en) * 2002-09-18 2004-04-01 Hanauske-Abel Hartmut M INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE AND USES THEREFOR
US20050245745A1 (en) * 2004-04-29 2005-11-03 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

Also Published As

Publication number Publication date
WO2004075831A2 (en) 2004-09-10
WO2004075831A3 (en) 2004-11-25
US20060159622A1 (en) 2006-07-20
EP1597267A4 (en) 2007-04-18
CA2515129A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
Khanna et al. Substrate Specificity, Gene Structure, and Tissue-specific Distribution of Multiple Human 3α-Hydroxysteroid Dehydrogenases (∗)
Storbeck et al. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?
Ohtani et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker
Yau et al. Dehydroepiandrosterone 7-hydroxylase cyp7b: predominant expression in primate hippocampus and reduced expression in alzheimer's disease☆
Park et al. Acetylation of histone H3 at lysine 9 by ethanol in rat hepatocytes
Krakowiak et al. Lathosterolosis: an inborn error of human and murine cholesterol synthesis due to lathosterol 5-desaturase deficiency
Chou et al. Metabolic activation of N-hydroxy arylamines and N-hydroxy heterocyclic amines by human sulfotransferase (s)
Xie et al. Analysis of transcriptome and metabolome profiles alterations in fatty liver induced by high-fat diet in rat
Siu et al. Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5
Sooy et al. Partial deficiency or short-term inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves cognitive function in aging mice
Morris et al. Sex differences in pulmonary hypertension
Dickmann et al. Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy
Yang et al. Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes
Kishimoto et al. Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain
Samy et al. Divergent immune responses in male and female mice after trauma-hemorrhage: dimorphic alterations in T lymphocyte steroidogenic enzyme activities
Gallagher et al. Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity
Larionov et al. Aromatase in skeletal muscle
Salen et al. Sitosterolemia
Wassif et al. Residual cholesterol synthesis and simvastatin induction of cholesterol synthesis in Smith–Lemli–Opitz syndrome fibroblasts
Liu et al. Cytochrome P450 17α hydroxylase/17, 20 lyase (CYP17) function in cholesterol biosynthesis: identification of squalene monooxygenase (epoxidase) activity associated with CYP17 in Leydig cells
Tsai-Morris et al. The rat 17β-hydroxysteroid dehydrogenase type III: molecular cloning and gonadotropin regulation
Nitta et al. Evaluation of 4β-hydroxycholesterol and 25-hydroxycholesterol as endogenous biomarkers of CYP3A4: study with CYP3A-humanized mice
Alberts et al. Effect of high-fat diet on KKAy and ob/ob mouse liver and adipose tissue corticosterone and 11-dehydrocorticosterone concentrations
Ribas et al. Selective screening of Niemann–Pick type C Brazilian patients by cholestane-3β, 5α, 6β-triol and chitotriosidase measurements followed by filipin staining and NPC1/NPC2 gene analysis
Stoffel-Wagner et al. Expression of 5α-reductase in the human temporal lobe of children and adults

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050921

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/04 20060101ALI20070301BHEP

Ipc: C12Q 1/32 20060101ALI20070301BHEP

Ipc: G01N 33/92 20060101AFI20070301BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070315

17Q First examination report despatched

Effective date: 20070620

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080103